A Placebo-Controlled, Randomized, Double-Blind Study of Adjunctive Bupropion Sustained Release in the Treatment of SSRI-Induced Sexual Dysfunction

DeBattista, Charles; Solvason, Brent; Poirier, Jennifer; Kendrick, Ellen; Loraas, Emily

doi:10.4088/jcp.v66n0706

Cited by 69 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A randomized, blinded placebocontrolled trial 26 found no improvement in sexual function on any parameter included in the ASES or Brief Index of Sexual Functioning. In this study, 41 patients received bupropion augmentation (150 mg/day) of their current SSRI.…”

Section: Switch To or Add Bupropionmentioning

confidence: 99%

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Francois¹,

Levin²,

Kutscher³

et al. 2017

Psychiatric Annals

View full text Add to dashboard Cite

show abstract

Section: Switch To or Add Bupropionmentioning

confidence: 99%

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Francois¹,

Levin²,

Kutscher³

et al. 2017

Psychiatric Annals

View full text Add to dashboard Cite

show abstract

“…Buproprion is a dopamine and norepinephrine reuptake inhibitor that has been an effective antidote for the side effect of DE from SSRIs in some studies (Labbate et al, 1997;Ashton & Rosen, 1998;DeBattista et al, 2005). Many of the other drugs commonly used for DE have also been investigated as a treatment to counter the effects of SSRIs.…”

Section: Discussionmentioning

confidence: 99%

How is delayed ejaculation defined and treated in North America?

et al. 2015

View full text Add to dashboard Cite

SUMMARYDelayed ejaculation (DE) is an uncommon disorder that is difficult to treat because it is poorly understood. The aim was to evaluate the current opinion and clinical management of DE by practitioners in sexual medicine. Members of the Sexual Medicine Society of North America (SMSNA) were invited by email to participate in a web-based survey. The questionnaire consisted of eight questions pertaining to DE. Questions addressed patient volume, qualification of patient bother, ranking of etiologies, perceived success, treatments used, quantification of symptom resolution, and broad characterization of practitioner type. A total of 94 respondents completed the survey with 73% of those being urologists. Fifty-nine percent of the respondents saw ≤ 2 patients a month with DE and 89% of practitioners felt that DE was moderately or severely bothersome to the patients. Etiology was felt to be from medications and psychological factors primarily. Despite treatment modality, 'seldom' success was obtained for 49% of the time and 'never' for 11%. Carbergoline was the most common selected medication for DE. Academic and private urologists reported 'never' or 'seldom' success with sexual counseling compared to other practitioners, respectively (p = 0.008 and p = 0.001). Respondents who saw ≤ 2 patients per month often reported normalization of hypogonadism 'never' or 'seldom' corrected DE (p = 0.047). Delayed ejaculation is still a poorly understood disorder with inconsistent practice patterns seen among members of the SMSNA. A better understanding of this vexing disorder is needed with efforts placed on research and practitioner education.

show abstract

“…[36][37][38] Although bupropion may reverse SSRI-induced sexual dysfunction, it is still unclear whether bupropion is useful in treating sexual dysfunctions caused by other etiologies. [39][40][41] However, the fact that antidepressant-related sexual dysfunction can be managed pharmacologically indicates the importance of CNSacting neurotransmitters in the sexual cycle. 42 Other CNS targets A number of other CNS targets have been proposed for their impact on sexual function.…”

Section: Serotoninmentioning

confidence: 99%

Clinical applications of centrally acting agents in male sexual dysfunction

Hellstrom

2008

Int J Impot Res

View full text Add to dashboard Cite

Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, serotonin and the melanocortin systems. Investigations to determine the utility of centrally acting agents as monotherapy or adjunctive therapy in men with ED or other forms of sexual dysfunction are underway. Bremelanotide, a melanocortin agonist, has been tested in men with ED and may prove to be one of the first centrally acting agents to have clinical utility in male sexual dysfunction.

show abstract

A Placebo-Controlled, Randomized, Double-Blind Study of Adjunctive Bupropion Sustained Release in the Treatment of SSRI-Induced Sexual Dysfunction

Cited by 69 publications

References 0 publications

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

How is delayed ejaculation defined and treated in North America?

Clinical applications of centrally acting agents in male sexual dysfunction

Contact Info

Product

Resources

About